Public Employees Retirement System of Ohio increased its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 16.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,980 shares of the biotechnology company’s stock after buying an additional 3,625 shares during the period. Public Employees Retirement System of Ohio owned 0.14% of Enanta Pharmaceuticals worth $800,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. State Street Corp raised its position in Enanta Pharmaceuticals by 71.5% in the fourth quarter. State Street Corp now owns 568,238 shares of the biotechnology company’s stock worth $19,036,000 after buying an additional 236,871 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Enanta Pharmaceuticals by 129.7% in the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock worth $12,723,000 after buying an additional 233,265 shares during the last quarter. Candriam Luxembourg S.C.A. raised its position in Enanta Pharmaceuticals by 50.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 356,000 shares of the biotechnology company’s stock worth $10,965,000 after buying an additional 120,000 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Enanta Pharmaceuticals during the first quarter worth approximately $1,731,000. Finally, Vanguard Group Inc. raised its position in Enanta Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 792,165 shares of the biotechnology company’s stock worth $24,399,000 after buying an additional 53,007 shares during the last quarter. 65.85% of the stock is owned by hedge funds and other institutional investors.
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) opened at 37.96 on Friday. Enanta Pharmaceuticals, Inc. has a 1-year low of $21.52 and a 1-year high of $41.20. The company’s 50-day moving average price is $37.76 and its 200 day moving average price is $32.76. The company’s market cap is $724.66 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The business had revenue of $7.51 million during the quarter, compared to the consensus estimate of $8.08 million. During the same quarter in the prior year, the firm earned ($0.06) EPS. The business’s revenue was down 46.3% on a year-over-year basis. On average, analysts predict that Enanta Pharmaceuticals, Inc. will post $0.90 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was published by BNB Daily and is owned by of BNB Daily. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/public-employees-retirement-system-of-ohio-has-800000-stake-in-enanta-pharmaceuticals-inc-enta-updated-updated.html.
ENTA has been the subject of a number of analyst reports. Zacks Investment Research lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 12th. ValuEngine raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. JMP Securities raised Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price objective for the company in a research note on Tuesday, July 11th. Finally, Robert W. Baird lifted their price objective on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, August 8th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Enanta Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $36.00.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.